Brivaracetam for the treatment of epilepsy

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 12, 2011, Pages 1959-1966

  Schulze Bonhage, Andreas ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antiepileptic therapy; Brivaracetam; Genetic epilepsy; Levetiracetam; Mechanism of action; Pharmacodynamics; Pharmacokinetics; Progressive myoclonus epilepsy; Structural epilepsy

Indexed keywords

BRIVARACETAM; CARBAMAZEPINE; CELL PROTEIN; DIAZEPAM; ESLICARBAZEPINE ACETATE; ETIRACETAM; GABAPENTIN; OXCARBAZEPINE; PENTETRAZOLE; PHENYTOIN; PLACEBO; SODIUM CHANNEL; SYNAPSE VESICLE PROTEIN 2A; UNCLASSIFIED DRUG;

ADD ON THERAPY; AGITATION; ALERTNESS; AREA UNDER THE CURVE; ATTENTION; BINDING AFFINITY; BINDING SITE; BLURRED VISION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FOCAL EPILEPSY; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; MOTOR CONTROL; MYOCLONUS EPILEPSY; NAUSEA; NEUTROPENIA; NONHUMAN; PHOTOSENSITIVE EPILEPSY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTICONVULSANTS; DRUG INTERACTIONS; EPILEPSIES, PARTIAL; EPILEPSY; HUMANS; MEMBRANE GLYCOPROTEINS; MYOCLONIC EPILEPSIES, PROGRESSIVE; NERVE TISSUE PROTEINS; PYRROLIDINONES;

EID: 79960445898     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.591380     Document Type: Review

References (47)

1. Rogawski M. Brivaracetam: a rational drug discovery success story. Br J Pharmacol 2008;154:1555-7
2. Gazzola DM, Blacer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007;48:1303-7 (Pubitemid 47063094)
3. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007;62:375-81 (Pubitemid 350105951)
4. Zaccara G, Messori A, Cincotta M, Burchini G. Omparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies. Acta Neurol Scand 2006;114:157-68 (Pubitemid 44185908)
5. Lynch BA, Lambeng N, Nocka K, et al. The synaptic visicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;26:9861-6 (Pubitemid 38869327)
6. Kaminski R, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target. Neuropharmacology 2008;54:715-20
7. Matagne A, Klitgaard H, Kaminski R. Brivaracetam displays seizure protection superior to levetiracetam in phenytoin-resistant amygdala-kindled mice. Epilepsia 2008;49:115
8. Kenda B, Matagne A, Talaga P, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004;47:530-49 (Pubitemid 38129712)
9. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs. From basic science to novel clinical applications to CNS disorders. Drugs 2010;70:287-312
10. Kaminski R, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 2009;50:387-97
11. Wasterlein C, Suchomelova L, Matagne A, et al. Brivaracetam is a protein anticonvulsant in experimental status epilepticus. Epilepsia 2005;46:219-20
12. Tai T, Truong D. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm 2007;114:1547-51 (Pubitemid 350212011)
13. Malawska B, Kulig K, Brivaracetam UCB. Current oppinion in investigational drugs. 2005;6:740-6
14. Kostyuk P, Lukyanetz E, Klitgaard H, Margineanu D. UCB34714 a new pyrrolidone derivative, without impact on high-and-low voltage activated calcium currents in rat isolated neurons. Epilepsia 2004;45:141-2
15. Margineanu D, Schlobohm I, Klitgaard H. UCB34714 a new pyrrolidone anticonvulsant, had no effect on voltage-gated potassium currents in cultured mouse hippocampal neurons. Epilepsia 2004;45:116
16. Zona C, Pieri M, Carunchio I, et al. Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture. Epilepsy Res 2010;88:46-54
17. Sargentini-Maier M, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 2006;63:680-8 (Pubitemid 46753569)
18. Sargentini-Maier M, Espie P, Coquette A, Stockis A. Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in healthy subjects. Drug Metab Dispos 2008;36:36-45
19. Hulhoven R, Scheen A, Watanabe S, et al. Bioavailability and safety of the intravenous administration of Brivaracetam. Epilepsia 2008;49:438
20. Valgaeren A, Hulhoven R, Scheen A, et al. Biavailability and safety of intavenous brivaracetam in healthy subjects. Epilepsia 2009;50:96
21. Whomsley R, Brochot A, Dell'Aiera S, et al. Identification of the cytochrome P450 isoforms responsible for the hydroxylation of Brivaracetam. AAPS J 2007;9:3408
22. Hulhoven R, Scheen A, Watanabe S, et al. Brivaracetam CYP2C8 interaction study in healthy subjects. Abstracts/Therty-seventh annual ACCP meeting Abstracts; 2010, p. 1111
23. von Rosenstiel P. Brivaracetam UCB 34714. Am Soc Exp Neuro Ther 2007;4:84-7
24. Stockis A, Jacobs T, Leonard M, Sargentini-Maier M. Pharmacokinetics of Brivaracetam in subjects with severe renal impairment. Epilepsia 2010;51:122-3
25. Kasteleijn-Nolst Trenite D, Parain D, Masnou P, et al. New analogue of Levetiracetam Brivaracetam and its efficacy in the photosensitivity model. Epilepsia 2005;46:56
26. Kalviaiinen R, Genton P, Andermann E, et al. Brivaracetam in patients with Unverricht-Lundborg disease, results from two randomized, placebo-controlled, double-blind studies. Epilepsia 2009;50:47
27. von Rosenstiel P. Overview of Brivaracetam for progressive myoclonic epilepsies. Epilepsia 2006;47:238
28. French J, Costantini C, Brodsky A, von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures. Neurology 2010;75:519-25
29. van Paesschen W, Brodsky A. Efficacy and tolerability of 50 and 150 mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset epilepsy. Epilepsia 2007;48(S6):329
30. Bilton V, Werhahn K, Johnson M, et al. Brivaracetam as adjunctive treatment of refractory partial-onset seizures in adults: results from two randomized, double-blind, placebo-controlled trials. Epilepsia 2009;50:106
31. Brochot A, Zamacona M, Stockis A. Physiologically based pharmacokineticpharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. Nordic Pharmacol Soc Basic Clin Pharmacol Toxicol 2010;106:256-62
32. Matagne A, Margineanu D, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008;154:1662-71
33. Rogawski M. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res Section 2006;69(12):273-94 (Pubitemid 44209049)
34. Kasteleijn-Nolst Trenite D, Genton P, Parain D, et al. Evaluation of brivaracetam a novel SV2A ligand in the photosensitivity model. Epilepsia 2009;46:56
35. Rolan P, Pigeolet E, Stockis A. UCB 34714: single and multiple rising does safety, tolerability and pharmacokinetics in healthy subjects. Epilepsia 2004;45:314-15
36. Brodsky A, Constantini C, von Rosenstiel P. Safety and tolerability of Brivaracetam as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2007;48:342-3
37. Kwan P, Johnson M, Falter U, et al. Safety and tolerability of brivaracetam as adjunctive treatment in adults with refractory epilepsy randomized, double-blind, placebo-controlled trial. Epilepsia 2009;50:107-8
38. Rossillon D, Astruc B, Bendahmane R, et al. Brivaracetam thorough QT Study: lack of proarrhythmic effect. Epilepsia 2007;48:329
39. Sharief MK, Singh P, Sander JW, et al. Efficacy and tolerability study of UCB LO59 in patients with refractory epilepsy. Epilepsia 1996;9:106-12 (Pubitemid 26227170)
40. Otoul C, Stockis A, Burton I, et al. Single dose bioequivalence between brivaracetam oral solution formulation and oral film-coated tablet in healthy sujects. Epilepsia 2009;50:96
41. Malawska B, Kulig K. Brivaracetam: a new drug indevelopment for epilepsy and neuropathic pain. Expert Opin Drug Eval 2008;17:361-9 (Pubitemid 351578188)
42. Schulze-Bonhage A, Feil B, Fauser S, Homberg V. Levetiracetam in combined therapy for focal epilepsy experience with 80 patients. Nervenarzt 2004;75:749-54 (Pubitemid 39141724)
43. Somerville ER, McLaughlin DB, Robinson MK, Berkovic SF. Adjunctive therapy of uncontrolled partial seizures with levetiracetam in Australian patients. Epilepsy Behav 2007;11:338-42 (Pubitemid 350048482)
44. Genton P. When antiepilepticdrugs aggravate epilepsy. Brain Dev 2000;22:75-80
45. Anonymus: Eslicarbazepinazetat (Zebinix) gegen partielle Anfalle Arzneimitteltelegramm. Available from: http://www.arzneitelegrammde/html/2009- 10/0410104-01.html 2009.106-7
46. Schulze-Bonhage A. Epilepsies and their medical treatment. Med Monatsschr Pharm 2010;33:207-14
47. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction. Epilepsy Behav 2011;20:20-3